Development of a pill designed to boost sex drive in women has been halted, the German manufacturer said.
Boehringer Ingelheim GmbH said this followed a sceptical response from US regulators.
The company said it made the decision because of the "complexity and extent of further questions that would need to be addressed to potentially obtain registration".
In a review in June, the Food and Drug Administration said two Boehringer studies failed to show a significant increase in sexual desire in women who took the drug as recorded by them in a daily journal.
The company said that despite its decision it "continues to believe in the value" that its drug, called flibanserin, could have.
Boehringer Ingelheim said it would reallocate resources to areas such as stroke prevention, diabetes and cancer.